US10383876 — Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
Composition of Matter · Assigned to Bayer Intellectual Property GmbH · Expires 2032-03-29 · 6y remaining
What this patent protects
This patent protects a specific chemical compound, 2-amino-N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydroimidazo-[1,2-c]quinazolin-5-yl]pyrimidine-5-carboxamide dihydrochloride salt, and methods for preparing it.
USPTO Abstract
The present invention relates:âto 2-amino-N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydroimidazo-[1,2-c]quinazolin-5-yl]pyrimidine-5-carboxamide dihydrochloride salt of formula (II): or a tautomer, solvate or hydrate thereof;âto methods of preparing said dihydrochloride salt;âto said dihydrochloride salt for the treatment and/or prophylaxis of a disease;âto the use of said dihydrochloride salt for the preparation of a medicament for the treatment and/or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, more particularly for the treatment or prophylaxis of a cancer, particularly lung cancer, in particular non-small cell lung carcinoma, colorectal cancer, melanoma, pancreatic cancer, hepatocyte carcinoma, pancreatic cancer, hepatocyte carcinoma or breast cancer;âto a pharmaceutical composition comprising said dihydrochloride salt; andâto a pharmaceutical combination comprising said dihydrochloride salt in combination with one or more further pharmaceutical agents.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.